Results 121 to 130 of about 12,325 (181)

5‑Nitrofuran-Semicarbazone Hybrids as Antitrypanosomal Agents: Structure-Activity Relationship and Nitroreductase Activation. [PDF]

ACS Med Chem Lett
Alegbejo Price TO, Silva DG, Vaidergorn MM, Augusto BS, Matheeussen A, Van Pelt N, Caljon G, Riley J, Read KD, Medina-Franco JL, Nonato MC, Emery FS.   +11 more
europepmc   +1 more source

A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate. [PDF]

J Antimicrob Chemother
Hendrickx S, Ilbeigi K, Thoré ESJ, Bertram MG, Calvo-Alvarez E, Cintesun S, Olías-Molero AI, Corral MJ, Mateo-Barrientos M, Estaquier J, Pomel S, Alunda JM, Gul S, Van Bocxlaer K, Frézard F, Tavares J, Cordeiro Da Silva A, Costi MP, Maes L, Caljon G.   +19 more
europepmc   +1 more source

The Burden of Neglected Tropical Diseases in Rwanda: A Scoping Review. [PDF]

Health Sci Rep
Mutsaka-Makuvaza MJ, Binuyo MO, Cyuzuzo C, Igizeneza A, Sinumvayo JP, Ajakaye OG, Enabulele EE, Chinwadzimba Z, Agwu E, Midzi N.   +9 more
europepmc   +1 more source

A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage. [PDF]

J Antimicrob Chemother
Hendrickx S, Ilbeigi K, Thoré ESJ, Bertram MG, Calvo-Alvarez E, Cintesun S, Olías-Molero AI, Corral MJ, Mateo-Barrientos M, Estaquier J, Pomel S, Alunda JM, Gul S, Van Bocxlaer K, Frézard F, Tavares J, Da Silva AC, Costi MP, Maes L, Caljon G.   +19 more
europepmc   +1 more source

Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment. [PDF]

Pharmaceuticals (Basel)
Ebiloma GU, Alhejeli A, de Koning HP.
europepmc   +1 more source

Development of a camelid single-domain antibody-based antigen detection assay for the pan-specific diagnosis of active human and animal <i>Trypanosoma brucei</i> infections. [PDF]

J Clin Microbiol
Li Z, Jin B-k, Moreno EET, Álvarez-Rodríguez A, Ginderachter JAV, Radwanska M, Sterckx YG-J, Stijlemans B, Magez S.   +8 more
europepmc   +1 more source

Control of human African trypanosomiasis in the Quiçama focus, Angola

Bulletin of the World Health Organization, 2002
Ruiz José Antonio, Simarro Pere P., Josenando Teofilo   +2 more
doaj  

Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study.

Lancet Glob Health
Kumeso VKB, Perdrieu C, Menétrey C, Kyhi MIW, Tete DN, Camara M, Tampwo J, Kavunga P, Camara ML, Kourouma A, Mindele WK, Masa FA, Mahenzi H, Makaya J, Malu TM, Mandula G, Nzambi DMM, Ntoya SL, Reymondier A, Kalonji WM, Scherrer B, Mordt OV.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Human African trypanosomiasis

Infectious Disease Clinics of North America, 2012
Abstract Human African trypanosomiasis (sleeping sickness) is caused by subspecies of the protozoan parasite Trypanosoma brucei. The disease is restricted to tropical Africa where it is transmitted by the bite of infected tsetse flies (Glossina spp.).
Brun, R., Blum, J.
openaire   +3 more sources

African trypanosomiasis

Annals of Tropical Medicine & Parasitology, 2006
Trypanosomiasis remains one of the most serious constraints to economic development in sub-Saharan Africa and, as a consequence, related research has been subject to strong social and political as well as scientific influences. The epidemics of sleeping sickness that occurred at the turn of the 20th Century focussed research efforts on what became ...
openaire   +3 more sources